The estimated Net Worth of Holdings, Inc. Bio Xcel is at least $19.3 Million dollars as of 25 June 2021. Holdings Xcel owns over 473,250 units of BioXcel Therapeutics Inc stock worth over $4,700,713 and over the last 4 years Holdings sold BTAI stock worth over $14,590,298.
Holdings has made over 1 trades of the BioXcel Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Holdings sold 473,250 units of BTAI stock worth $14,590,298 on 25 June 2021.
The largest trade Holdings's ever made was selling 473,250 units of BioXcel Therapeutics Inc stock on 25 June 2021 worth over $14,590,298. On average, Holdings trades about 236,625 units every 0 days since 2020. As of 25 June 2021 Holdings still owns at least 8,546,750 units of BioXcel Therapeutics Inc stock.
You can see the complete history of Holdings Xcel stock trades at the bottom of the page.
Holdings's mailing address filed with the SEC is 2614 BOSTON POST ROAD, SUITE 33B, GUILFORD, CT, 06437.
Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over $63,244,788 worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth $321,105 . The most active insiders traders include Vimal Bio Xcel Holdings, In..., Vimal Mehta, and Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $29,814. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth $413.
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include: